Investment Risk Analysis: LIMBS & THINGS LIMITED

1. Risk Rating: LOW-MEDIUM

Justification: The company demonstrates fundamental operational strength with 33+ years of trading history, consistent profitability, and a clean audit opinion with no going concern qualifications. However, the aggressive dividend extraction in 2023—nearly double the year's after-tax profit—has materially weakened the balance sheet, with net assets declining approximately 19.5% and cash reserves falling 44% year-over-year. While the business remains solvent with adequate liquidity at present, the dividend policy warrants close monitoring.

2. Key Concerns

i) Dividend Distribution Significantly Exceeds Earnings

The company paid £9.95M in dividends against post-tax profit of £5.44M—a payout ratio of approximately 183%. This has drawn down accumulated reserves and contributed to the decline in both net assets and cash. While legally permissible given historical reserves, sustained extraction at this level would erode the balance sheet and constrain future investment capacity.

ii) Material Deterioration in Balance Sheet Strength

Net assets fell from £24.1M (2022) to £19.4M (2023), a decline of approximately £4.7M or 19.5%. Cash reserves dropped from £14.8M to £8.3M—a £6.5M or 44% reduction. Total assets also declined from £29.6M to £23.7M. This compression reduces the company's financial resilience against trading downturns or unexpected liabilities.

iii) Growth Deceleration and Market Headwinds

The strategic report explicitly acknowledges that growth has slowed from previous years, attributing prior performance partly to "pent-up demand following the disruption caused by the Covid pandemic" which "has effectively now faded." With inflationary pressures on raw materials, increasing competition in the medical simulation sector, and geopolitical uncertainties noted by directors, the trajectory of revenue growth requires observation.

3. Positive Indicators

• Profitable Operations: Post-tax profit of £5.44M on turnover of £32.4M represents a healthy net margin of approximately 16.8%, demonstrating pricing power and operational efficiency.

• Clean Audit Opinion: Forvis Mazars LLP issued an unqualified opinion with no material uncertainties regarding going concern, providing independent validation of the financial statements.

• Strong Ownership Stability: PSC register shows Mrs Carolyn Margot Cooper (50-75% ownership) and Mr Nicholas Paul Riley (25-50% ownership) as long-term committed shareholders, aligning ownership with control.

• Compliance Record: No overdue filings with Companies House. Accounts and confirmation statements are current, indicating sound administrative governance.

• Strategic Investment: The acquisition of eoSurgical Ltd for laparoscopic simulation technology and the exclusive Trucorp partnership demonstrate proactive market positioning. Further property acquisitions planned for 2024 to expand production capacity signal confidence in future demand.

• Product Quality Focus: 84% of sales from own-manufactured products (up from 82%) indicates strengthening brand value and customer acceptance, reducing reliance on third-party distribution.

4. Due Diligence Notes

a) Dividend Policy and Future Intentions

Clarify whether the £9.95M dividend represents a one-time extraction (possibly for shareholder restructuring or estate planning given the company's longevity) or signals a shift toward higher ongoing distributions. Understanding the rationale is critical for projecting future retained earnings and reinvestment capacity.

b) Cash Flow Reconciliation

The decline in cash of £6.5M alongside dividends of £9.95M and profit of £5.44M suggests operating cash generation was insufficient to cover both dividends and working capital/capital expenditure requirements. A detailed cash flow analysis would reveal whether this reflects temporary working capital movements or a more structural mismatch.

c) eoSurgical Ltd Acquisition Details

The strategic report notes the acquisition has not delivered "material increase in sales" but provides future technology benefits. Assess the purchase price, goodwill recognised, integration progress, and timeline for revenue contribution to evaluate whether this represents prudent investment or capital at risk.

d) Working Capital and Creditor Position

Total liabilities reduced from £5.06M to £3.81M while cash fell more sharply. Investigate whether supplier payment terms have been extended or whether the liability reduction reflects normal trade cycle timing. The relationship between current assets and current liabilities should be examined for working capital adequacy.

e) Related Party Transactions

Given the concentrated ownership structure (two PSCs controlling 75-100% between them), review the full accounts for any related party transactions, particularly regarding the significant dividend distribution, director remuneration, and any intercompany balances with subsidiaries.

f) Property Acquisition Plans

The 2024 plan to purchase "two nearby properties" to increase production capacity requires assessment of the capital commitment, funding mechanism (debt vs. cash), and projected return on investment given the already reduced cash position.